The FDA has approved the combination of lenvatinib and everolimus to treat 
advanced or metastatic renal cell carcinoma. The approval marks the first time 
that tyrosine kinase and mTOR inhibitors have been combined successfully as 
second-line treatment for renal cell carcinoma following prior VEGF-targeted 
therapy.